Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-06-30
2004-02-17
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S399000
Reexamination Certificate
active
06693077
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility. In addition, this invention relates to a method of purifying the KGF-2 polypeptide.
BACKGROUND OF THE INVENTION
The fibroblast growth factor family has emerged as a large family of growth factors involved in soft-tissue growth and regeneration. It presently includes several members that share a varying degree of homology at the protein level, and that, with one exception, appear to have a similar broad mitogenic spectrum, i.e., they promote the proliferation of a variety of cells of mesodermal and neuroectodermal origin and/or promote angiogenesis.
The pattern of expression of the different members of the family is very different, ranging from extremely restricted expressions of some stages of development, to rather ubiquitous expression in a variety of tissues and organs. All the members appear to bind heparin and heparin sulfate proteoglycans and glycosaminoglycans and strongly concentrate in the extracellular matrix. KGF was originally identified as a member of the FGF family by sequence homology or factor purification and cloning. Keratinocyte growth factor (KGF) was isolated as amitogen for a cultured murine keratinocyte line (Rubin, J. S. et al.,
Proc. Natl. Acad Sci. USA
86:802-806 (1989)). Unlike the other members of the FGF family, it has little activity on mesenchyme-derived cells but stimulates the growth of epithelial cells. The Keratinocyte growth factor gene encodes a 194-amino acid polypeptide (Finch, P. W. et al.,
Science
245:752-755 (1989)). The N-terminal 64 amino acids are unique, but the remainder of the protein has about 30% homology to bFGF. KGF is the most divergent member of the FGF family. The molecule has a hydrophobic signal sequence and is efficiently secreted. Post-translational modifications include cleavage of the signal sequence and N-linked glycosylation at one site, resulting in a protein of 28 kDa. Keratinocyte growth factor is produced by fibroblast derived from skin and fetal lung (Rubin et al. (1989)). The Keratinocyte growth factor mRNA was found to be expressed in adult kidney, colon and ilium, but not in brain or lung (Finch, P. W. et al.
Science
245:752-755 (1989)). KGF displays the conserved regions within the FGF protein family. KGF binds to the FGF-2 receptor with high affinity.
Impaired wound healing is a significant source of morbidity and may result in such complications as dehiscence, anastomotic breakdown and, non-healing wounds. In the normal individual, wound healing is achieved uncomplicated. In contrast, impaired healing is associated with several conditions such as diabetes, infection, immunosuppression, obesity and malnutrition (Cruse, P. J. and Foord, R.,
Arch. Surg
. 107:206 (1973); Schrock, T. R. et al.,
Ann. Surg
. 177:513 (1973); Poole, G. U., Jr.,
Surgery
97:631 (1985); Irvin, G. L. et al.,
Am. Surg
. 51:418 (1985)).
Wound repair is the result of complex interactions and biologic processes. Three phases have been described in normal wound healing: acute inflammatory phase, extracellular matrix and collagen synthesis, and remodeling (Peacock, E. E., Jr.,
Wound Repair
, 2nd edition, WB Saunders, Philadelphia (1984)). The process involves the interaction of keratinocytes, fibroblasts and inflammatory cells at the wound site.
Tissue regeneration appears to be controlled by specific peptide factors which regulate the migration and proliferation of cells involved in the repair process (Barrett, T. B. et al.,
Proc. Natl. Acad. Sci. USA
81:6772-6774 (1985); Collins, T. et al.,
Nature
316:748-750 (1985)). Thus, growth factors may be promising therapeutics in the treatment of wounds, burns and other skin disorders (Rifkin, D. B. and Moscatelli,
J. Cell. Biol
. 109:1-6 (1989); Sporn, M. B. et al,
J. Cell. Biol
. 105:1039-1045 (1987); Pierce, G. F. et al,
J. Cell Biochem
. 45;319-326 (1991)). The sequence of the healing process is initiated during an acute inflammatory phase with the deposition of provisional tissue. This is followed by re-epithelialization, collagen synthesis and deposition, fibroblast proliferation, and neovascularization, all of which ultimately define the remodeling phase (Clark, R. A. F.,
J. Am. Acad. Dermatol
. 13:701 (1985)). These events are influenced by growth factors and cytokines secreted by inflammatory cells or by the cells localized at the edges of the wound (Assoian, R. K. et al.,
Nature
(Lond.) 309:804 (1984); Nemeth, G. G. et al., “Growth Factors and Their Role in Wound and Fracture Healing,”
Growth Factors and Other Aspects of Wound Healing in Biological and Clinical Implications
, New York (1988), pp. 1-17.
Several polypeptide growth factors have been identified as being involved in wound healing, including keratinocyte growth factor (KGF) (Antioniades, H. et al.,
Proc. Natl. Acad. Sci. USA
88:565 (1991)), platelet derived growth factor (PDGF)(Antioniades, H. et al.,
Proc. Natl. Acad. Sci. USA
88:565 (1991); Staiano-Coico, L. et al.,
Jour. Exp. Med
. 178:865-878 (1993)), basic fibroblast growth factor (bFGF) (Golden, M. A. et al.,
J. Clin. Invest
. 87:406 (1991)), acidic fibroblast growth factor (aFGF) (Mellin, T. N. et al.,
J. Invest. Dermatol
. 104:850-855 (1995)), epidermal growth factor (EGF) (Whitby, D. J. and Ferguson, W. J.,
Dev. Biol
. 147:207 (1991)), transforming growth factor-&agr; (TGF-&agr;) (Gartner, M. H. et al.,
Surg. Forum
42:643 (1991); Todd, R. et al.,
Am. J. Pathol
. 138;1307 (1991)), transforming growth factor-&bgr; (TGF-&bgr;) (Wong, D. T. W. et al.,
Am. J. Pathol
. 143:622 (1987)), neu differentiation factor (rNDF) (Danilenko, D. M. et al.,
J. Clin. Invest
. 95;842-851 (1995)), insulin-like growth factor I (IGF-1), and insulin-like growth factor II (IGF-II) (Cromack, D. T. et al.,
J. Surg. Res
. 42:622 (1987)).
It has been reported that rKGF-1 in the skin stimulates epidermal keratinocytes, keratinocytes within hair follicles and sebaceous glands (Pierce, G. F. et al.,
J. Exp. Med
. 179:831-840 (1994)).
SUMMARY OF THE INVENTION
The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding the keratinocyte growth factor (KGF-2) having the amino acid sequence as shown in
FIG. 1
[SEQ ID NO:2] or the amino acid sequence encoded by the cDNA clones deposited as ATCC Deposit Number 75977 on Dec. 16, 1994. The nucleotide sequence determined by sequencing the deposited KGF-2 clone, which is shown in
FIG. 1
[SEQ ID NO:1], contains an open reading frame encoding a polypeptide of 208 amino acid residues, including an initiation codon at positions 1-3, with a predicted leader sequence of about 35 or 36 amino acid residues, and a deduced molecular weight of about 23.4 kDa. The amino acid sequence of the mature KGF-2 is shown in
FIG. 1
, amino acid residues about 36 or 37 to 208 [SEQ ID NO:2].
The polypeptide of the present invention has been putatively identified as a member of the FGF family, more particularly the polypeptide has been putatively identified as KGF-2 as a result of amino acid sequence homology with other members of the FGF family.
In accordance with one aspect of the present invention, there are provided novel mature polypeptides which are KGF-2 as well as biologically active and diagnostically or therapeutically useful fragments, analogs and derivatives thereof. The polypeptides of the present invention are of human origin.
In accordance with another aspect of the present inve
Coleman Timothy A.
Dillon Patrick J.
Duan D. Roxanne
Gentz Reiner L.
Gruber Joachim R.
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Saoud Christine J.
LandOfFree
Keratinocyte growth factor-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Keratinocyte growth factor-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Keratinocyte growth factor-2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3350717